-
APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease mediated by autoimmunity, with its pathogenesis not yet fully understood. Traditionally, PBC was thought to predominantly affect Western populations, but in recent decades, there has been an increasing number of reported cases and published literature in the Asia-Pacific region, escalating the disease burden. In response,…
-
ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853
From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of “Oncology Insights” delved into the forefront, witnessing the outstanding performance of “China’s Good Voice” on the international…
-
ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity
Acute myeloid leukemia (AML) is a highly heterogeneous group with varying sensitivities to chemotherapy. The “7+3” regimen has been the standard induction chemotherapy for AML for 50 years. In the era of precision medicine, optimizing induction therapy for AML is a crucial issue. At the recent 65th American Society of Hematology (ASH) Annual Meeting, Professor…
-
ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML
From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered…
-
ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)
From December 9 to December 12, 2023, the 65th American Society of Hematology Annual Meeting (ASH) took place in San Diego. Experts from around the world in the field of hematologic malignancies gathered, presenting a wealth of exciting content. During this conference, Professor Huang Huiqiang and his team from Sun Yat-sen University Cancer Center reported…
-
ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting,…
-
ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma
In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,…
-
APASL 2023 | Prof. Rao Huiying: Eliminating HCV, Key Issues That Still Need Attention
Editor’s Note: Chronic HCV infection is a global public health issue. With the widespread use of direct-acting antiviral agents (DAAs), chronic hepatitis C (CHC) has become a curable disease. However,…
Connecting Medical Expertise through Media